Literature DB >> 22142836

Chronic obstructive pulmonary disease among adults aged 18 and over in the United States, 1998-2009.

Lara J Akinbami1, Xiang Liu.   

Abstract

Chronic obstructive pulmonary disease (COPD) causes substantial morbidity and mortality and may be unrecognized in its early stages. Chronic lower respiratory disease (CLRD), which includes both COPD and asthma, was the third leading cause of death in the United States in 2008. COPD includes chronic bronchitis and emphysema, which both make emptying air from the lungs progressively more difficult and can be associated with cough, mucus production, wheezing, and breathlessness. Risk factors include primarily cigarette smoking, but also exposure to noxious particles or gases, recurrent infection, diet, and genetic factors. COPD is often preventable, but there is no cure. Treatment can control symptoms and slow disease progression. This report presents trends in COPD prevalence, hospitalization, and death rates, and detailed recent estimates for population subgroups. Asthma is excluded from this report because it is considered a different condition with fully reversible symptoms, although some people may have asthma and COPD concurrently. All material appearing in this report is in the public domain and may be reproduced or copied without permission; citation as to source, however, is appreciated.

Entities:  

Mesh:

Year:  2011        PMID: 22142836

Source DB:  PubMed          Journal:  NCHS Data Brief        ISSN: 1941-4935


  52 in total

1.  Making Precision Medicine Socially Precise. Take a Deep Breath.

Authors:  Sam S Oh; Marquitta J White; Christopher R Gignoux; Esteban G Burchard
Journal:  Am J Respir Crit Care Med       Date:  2016-02-15       Impact factor: 21.405

Review 2.  Sex-specific lung diseases: effect of oestrogen on cultured cells and in animal models.

Authors:  Bosung Shim; Gustavo Pacheco-Rodriguez; Jiro Kato; Thomas N Darling; Martha Vaughan; Joel Moss
Journal:  Eur Respir Rev       Date:  2013-09-01

3.  All-Cause Mortality Among US Veterans of the Persian Gulf War: 13-Year Follow-up.

Authors:  Shannon K Barth; Han K Kang; Tim Bullman
Journal:  Public Health Rep       Date:  2016-10-27       Impact factor: 2.792

Review 4.  State of the Art Review: Physical Activity and Older Adults.

Authors:  Caroline A Macera; Alyson Cavanaugh; John Bellettiere
Journal:  Am J Lifestyle Med       Date:  2016-06-23

5.  Depression treatment patterns among adults with chronic obstructive pulmonary disease and depression.

Authors:  Arijita Deb; Usha Sambamoorthi
Journal:  Curr Med Res Opin       Date:  2016-11-11       Impact factor: 2.580

6.  Active asthma and the prevalence of physician-diagnosed COPD.

Authors:  Maria C Mirabelli; Suzanne F Beavers; Arjun B Chatterjee
Journal:  Lung       Date:  2014-06-21       Impact factor: 2.584

7.  Does Low FEV1 in Addition to Fixed Ratio and/or Lower Limit of Normal of FEV1/FVC Improve Prediction of Mortality in COPD? The NHANES-III-linked-mortality Cohort.

Authors:  Yewande E Odeyemi; O'Dene Lewis; Julius Ngwa; Kristen Dodd; Richard F Gillum; Alem Mehari
Journal:  J Natl Med Assoc       Date:  2018-07-29       Impact factor: 1.798

8.  Prevalence and Comorbidities of Chronic Obstructive Pulmonary Disease Among Adults in Kentucky Across Gender and Area Development Districts, 2011.

Authors:  Abdulbaset Kamour; Mannino David; Sarojini Kanotra
Journal:  Chronic Obstr Pulm Dis       Date:  2015-10-15

9.  Sex and Gender Differences in Lung Disease.

Authors:  Patricia Silveyra; Nathalie Fuentes; Daniel Enrique Rodriguez Bauza
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

10.  Stakeholder priorities for comparative effectiveness research in chronic obstructive pulmonary disease: a workshop report.

Authors:  Jerry A Krishnan; Peter K Lindenauer; David H Au; Shannon S Carson; Todd A Lee; Mary Ann McBurnie; Edward T Naureckas; William M Vollmer; Richard A Mularski
Journal:  Am J Respir Crit Care Med       Date:  2012-11-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.